Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

» Details

Guru Trades

Q2 2015

XLV Guru Trades in Q2 2015

Steven Cohen 6,200 sh (New)
Louis Moore Bacon 520,175 sh (+17.11%)
Ken Fisher 271,515 sh (+5.40%)
Jim Simons Sold Out
Leon Cooperman Sold Out
» More
Q3 2015

XLV Guru Trades in Q3 2015

Ken Fisher 285,985 sh (+5.33%)
Steven Cohen Sold Out
Louis Moore Bacon 73,000 sh (-85.97%)
» More
Q4 2015

XLV Guru Trades in Q4 2015

Jim Simons 53,500 sh (New)
Louis Moore Bacon 89,000 sh (+21.92%)
Ken Fisher 293,541 sh (+2.64%)
Louis Moore Bacon 35,000 sh (unchged)
» More
Q1 2016

XLV Guru Trades in Q1 2016

John Buckingham 32,049 sh (New)
Ken Fisher 298,675 sh (+1.75%)
Louis Moore Bacon 25,000 sh (-71.91%)
Jim Simons 11,200 sh (-79.07%)
» More

Ratios

vs
industry
vs
history
P/E(ttm) 22.89
XLV's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XLV: 22.89 )
Ranked among companies with meaningful P/E(ttm) only.
XLV' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 22.89
Current: 22.89
0
22.89
PE(NRI) 22.89
XLV's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XLV: 22.89 )
Ranked among companies with meaningful PE(NRI) only.
XLV' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 22.89
Current: 22.89
0
22.89
P/B 3.71
XLV's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XLV: 3.71 )
Ranked among companies with meaningful P/B only.
XLV' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 3.72
Current: 3.71
0
3.72

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.46
XLV's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XLV: 1.46 )
Ranked among companies with meaningful Dividend Yield only.
XLV' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 1.47
Current: 1.46
0
1.47
Yield on cost (5-Year) 1.46
XLV's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XLV: 1.46 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
XLV' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 1.47
Current: 1.46
0
1.47

More Statistics

Short Percentage of Float0.00%
52-Week Range $63.52 - 76.53
Shares Outstanding (Mil)99,999,999.99
» More Articles for XLV

Headlines

Articles On GuruFocus.com
S&P 500 Sector ETFs: A Look Under the Hood, Part 3 Mar 11 2015 
Build a “Whatever Happens” Portfolio – Now! Aug 15 2014 
Are Earnings Important? These Days, Revenues Count for More! Mar 17 2014 

More From Other Websites
GILD Developing Next Generation HCV Drugs to Remain Competitive Jul 22 2016
St. Jude Medical Gets ‘Hold’ Rating from 96% of Analysts Jul 22 2016
Is Vertex Pharmaceuticals Exposed to Drug Pricing Risks? Jul 22 2016
How Alexion Plans to Fuel Strensiq Sales Jul 22 2016
Why Johnson & Johnson’s 2Q16 Profits Fell by 11.5% Jul 22 2016
What Are Lilly’s 2Q16 Estimates and Expectations for Elanco? Jul 22 2016
Abbott’s 2Q16 Earnings Propelled by Impressive Sales Growth Jul 22 2016
Summer's top summer sector: Health care Jul 22 2016
3 Healthcare ETFs to Buy as JNJ Beats Q2 Earnings Jul 21 2016
4 Healthcare Mutual Funds to Buy on Bright Prospects Jul 21 2016
Behind the bull market Jul 20 2016
Richard Bernstein on Profits Recession and Portfolio Positioning Jul 20 2016
Dow ETF Notches Fresh Closing High As Blue Chip Stocks Take The Reins Jul 19 2016
Inside Bill Ackman’s Current Stance and View of His Holdings Jul 19 2016
How to Profit From Abbott Labs Jul 19 2016
For this rally to continue, there must be a change in leadership Jul 15 2016
Analysts’ Ratings of St. Jude Medical before 2Q16 Results Jul 15 2016
Analysts’ Latest Recommendations for Intuitive Surgical Jul 15 2016
Abbott Laboratories: Analyst Recommendations before 2Q16 Results Jul 14 2016
Could the Dow Jump Up Another 400 Points by Year-End? Jul 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK